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Abstract 1 
 2 
 3 
Ribosomes are nanomachines essential for protein production in all living cells. Ribosome 4 
synthesis increases in cancer cells to cope with a rise in protein synthesis and sustain unrestricted 5 
growth. This increase in ribosome biogenesis is reflected by severe morphological alterations of 6 
the nucleolus, the cell compartment where the initial steps of ribosome biogenesis take place. 7 
Ribosome biogenesis has recently emerged as an effective target in cancer therapy, and several 8 
compounds that inhibit ribosome production or function, killing preferentially cancer cells, have 9 
entered clinical trials. Recent research indicates that cells express heterogeneous populations of 10 
ribosomes and that the composition of ribosomes may play a key role in tumorigenesis, exposing 11 
novel therapeutic opportunities. Here, we review recent data demonstrating that ribosome 12 
biogenesis is a promising druggable pathway in cancer therapy, and discuss future research 13 
perspectives. 14 
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1. Introduction: Cancer cells are addicted to ribosome production 19 
 20 
 21 
In eukaryotes, the initial steps of ribosome production take place within specialized nuclear 22 
domains called nucleoli. Nucleoli are highly dense nuclear structures that assemble around the 23 
nucleolar organizers (NORs) containing the genes coding for ribosomal RNAs (rRNAs) [1]. For 24 
 3 
many years, changes in nucleolar morphology, nucleolar size, and number of nucleoli per nucleus 1 
have been recognized as hallmarks of malignity and tumor aggressiveness [2]. The analysis of 2 
nucleolar morphology, typically after specific staining (e.g. silver nitrate-based AgNOR), has been 3 
used by pathologists to establish the tumorigenic potential of cells in patient biopsies [2–5]. 4 
However, significant technical limitations, including in quantification and reproducibility, have 5 
prevented the routine implementation of such techniques by pathologists. Recently, the production 6 
of specific algorithms has addressed several of these limitations by providing tools to characterize 7 
nucleolar disruption both qualitatively (i.e. distinguishing patterns of disruption) and quantitatively 8 
(i.e. measuring severity of disruption), and by defining a precise numerical index: the ‘index of 9 
nucleolar disruption’ or iNo score [6,7]. Hopefully, such tools will be transformed into clinical 10 
applications in order to extend the use of nucleolar morphology to disease diagnosis and prognosis, 11 
and to integrate the nucleolus as a biomarker for improved patient stratification. 12 
The alterations of nucleolar morphology observed in cancer cells directly reflect the hyper 13 
activation of ribosome production. Importantly, it appears that tumor cells are addicted to increased 14 
ribosome production (and increased translational activity), since inhibition of these processes is 15 
generally cytotoxic. It is largely assumed that cancer cells become addicted to ribosomes owing to 16 
their enhanced need for protein production to sustain their unrestricted growth. The fact that 17 
inhibitors of translation, such as the one targeting the translation initiation machinery (mTOR 18 
inhibitors, eIF4F complex inhibitors), kill cancer cells supports such a concept of addiction [8–10]. 19 
In addition, the abnormal oncogenic signaling of cancer cells prevents the efficient feedback 20 
control that coordinates the synthesis of rRNAs and r-proteins, and eventually leads to nucleolar 21 
stress and apoptosis (see below). Increased ribosome biogenesis is a general trend in cancer cells 22 
[11–14], which is important for cell transformation and tumorigenesis, (see [15–17]), and it remains 23 
unclear why some tumor cells rely more than others on ribosome production and protein synthesis. 24 
 4 
Mechanistically, increased ribosome production in cancer cells is caused by the dysregulation of 1 
the three RNA polymerases by molecular mechanisms involving cancer-promoting proteins, 2 
including major oncogenic and tumor suppressive pathways, like c-Myc, mTOR, p53, pRb and 3 
PTEN (reviewed in details in [14,18]).  4 
Ribosome biogenesis is a complex process involving the synthesis, modification, assembly, and 5 
transport of eighty-four core ribosomal components: four rRNAs and eighty ribosomal proteins (r-6 
proteins) (Figure 1) [19]. It is highly energy-consuming, involves all three RNA polymerases (Pol), 7 
and most cell compartments as it is initiated in the nucleolus, progresses to the nucleoplasm, and 8 
ends in the cytoplasm [20]. Three of the four mature rRNAs are produced from a single long 9 
polycistronic precursor synthesized by RNA polymerase I (Pol I) requiring extensive processing 10 
(RNA cleavage), the fourth rRNA, namely the 5S, is produced by RNA Pol III [19], while r-11 
proteins are encoded in mRNAs synthesized by Pol II. All of these components work 12 
synergistically to ensure their faithful assembly into precursor (pre-) ribosomal subunits. This 13 
requires the participation of over 200 assembly factors. Each of these steps is closely regulated and 14 
intimately interconnected, to such a level that inhibiting one may severely impact another [21]. 15 
Finally, important quality control is exerted all along the pathway to ensure that only properly 16 
assembled ribosomes are produced [22].  17 
Ribosomes were traditionally considered to be a ‘monolithic block’, and it was believed that cells 18 
exclusively produce a single type of ribosome. It was recently shown that cells produce 19 
heterogeneous populations of ribosomes, the composition of which may differ, producing 20 
functional consequences on translation [23]. For instance, ribosomes may differ because their 21 
rRNAs are differentially modified (rRNAs contain over 200 modifications including the abundant 22 
2'-O-methylation, and pseudouridylation, as well as a dozen other base methylations, see below), 23 
or because an r-protein is absent or replaced by tissue-specific isoforms [24,25]. This, in turn, may 24 
 5 
impact the selection of mRNAs that ribosomes translate, thus influencing either normal processes, 1 
such as cell differentiation or embryogenesis, or disease etiology, such as cancer initiation and 2 
progression [26]. In this review, we will refer to “ribosome variants” when we discuss 3 
compositionally different ribosomes, to “specialized ribosomes”, when a specific function in the 4 
translation of specific mRNA transcripts has been attributed to these different ribosomes, and to 5 
“cancer ribosomes”, when specialized ribosomes have been associated with tumorigenesis. Despite 6 
the current efforts to systematically identify ribosome assembly factors in human cells [27–31], the 7 
fine molecular mechanisms and the kinetics of processing, assembly, nuclear export and quality 8 
control remain largely unexplored in humans compared to budding yeast (the historical reference 9 
model) [19,32].  10 
Until recently, targeting ribosomes to develop anticancer therapeutic strategies was not seriously 11 
envisaged for several reasons. Firstly, because human ribosome biogenesis is a highly complex 12 
process, the coordinated regulation of which is not fully deciphered. Secondly, because it involves 13 
the contribution of hundreds of cellular factors, many of which remain to be identified. Thirdly, 14 
and most importantly, because inhibiting ribosome biogenesis or function was expected to 15 
indistinctively kill healthy and diseased cells. Surprisingly, however, cancer cells are more 16 
sensitive to treatments that inhibit ribosome production. 17 
In this review, we summarize recent evidence supporting the notion that targeting ribosome 18 
biogenesis and/or function in cancer cells represents a promising strategy to develop specific 19 
powerful anticancer drugs. So far, such strategies have led to the development of several molecules 20 
that interfere with distinct steps of ribosome production and function, and some of these molecules 21 
have entered clinical trials (Figure 1).   22 
 23 
 24 
 6 
2. Targeting ribosome biogenesis for therapeutic intervention 1 
 2 
 3 
2.1 Targeting ribosome biogenesis at the level of rRNA synthesis 4 
1) Rationale and proof-of-concept 5 
The rationale for targeting ribosome biogenesis in cancer cells is based on the general observation 6 
that cancer cells produce more ribosomes and are thus likely to be more vulnerable to a reduction 7 
in ribosome production than healthy cells [13]. Historically, such a strategy was first attempted by 8 
using inhibitors of Pol I such as actinomycin D [33]. However, the limited specificity of 9 
actinomycin D, and its important toxicity towards cells, prevented its further development. 10 
Nonetheless, the effect on ribosome biogenesis of thirty-six drugs belonging to different chemical 11 
categories and routinely used in chemotherapeutic regimens was systematically investigated 12 
revealing that half of them displayed strong inhibitory effects on ribosome biogenesis by interfering 13 
specifically with either rRNA synthesis or pre-rRNA processing [34]. Quite unexpectedly, 14 
inhibition of ribosome biogenesis appears to represent the primary mode of action of some of these 15 
well-established anticancer compounds, as it was recently reported in the myc-driven Eμ-Myc 16 
Cdkn2aArf−/− lymphoma model for several platinum derivatives including oxaliplatin [35]. These 17 
data prompted the idea that targeting ribosome production may be a promising approach to develop 18 
innovative anticancer drugs.  19 
Proof-of-concept that targeted therapies which selectively inhibit ribosomal subunit biogenesis are 20 
efficient at killing cancer cells was made independently by Australian and American teams. They 21 
characterized several compounds, namely: CX-5461, CX-3543, and BMH-21 [36–39]), which 22 
selectively inhibit the function of Pol I (Figure 1 – Box 1). CX derivatives and BMH-21 act via 23 
distinct mechanisms. CX derivatives are G-quadruplex (G4) DNA motif binders while BMH-21 24 
 7 
binds to GC-rich DNA sequences [36,37,39,40]. Both G4 and GC-rich motifs are abundant in 1 
rDNA. CX derivatives inhibit the function of Pol I by preventing the binding of nucleolin and UBF 2 
(Upstream Binding Factor) [37,38], both of which are important for RNA synthesis, to Pol I 3 
promotors, while BMH-21 triggers the proteasomal-dependent degradation of the large catalytic 4 
subunit of Pol I [39]. Despite being DNA-binding molecules, these compounds were initially 5 
shown to not induce DNA damage in cultured cells, a feature that support their selectivity toward 6 
Pol I activity [36,37,39,40]. However, a recent study on DNA repair deficient cells raised the 7 
possibility that DNA damage might also contribute to their toxicity, at least in cells with particular 8 
genetic background ([41] and see below). In the original studies, the compounds were tested in 9 
vitro on a large panel of cancer cell lines representative of different types of cancers (NCI60 panel 10 
or an extended panel). For each of the three compounds, there was no association between the 11 
cancer of origin of the cell lines and the observed IC50 values, indicating that they do not have an 12 
organ-specific activity [37–39]. Yet, the IC50 values ranged from 90- to more than a 100-folds 13 
among cell lines for CX-5461 and BMH-21, respectively. This shows that these compounds have 14 
a selective toxicity toward cells with particular molecular profiles, which remain to be 15 
characterized. Once characterized, these molecular profiles might lead to identification of tumor 16 
subtypes that would benefit from treatment with these compounds. To date, CX-5461 has been the 17 
most extensively studied, and its anticancer activity has been reported in multiple cancer 18 
backgrounds, including: leukemia, lymphomas and myelomas [36,42–44], prostate [45], 19 
osteosarcoma [46], ovary [47] and neuroblastoma [48], illustrating the potentially broad 20 
applicability of such compounds. In addition to interfering with the function of Pol I, CX 21 
derivatives also cause severe replication and DNA repair issues since they stabilize G4 DNA motifs 22 
which form naturally within guanine-rich DNA sequences and consist of a four-stranded helical 23 
structure [41]. The tumor suppressor BRCA2 is important for replication fork stabilization and for 24 
 8 
DNA damage repair, including for repairing G-quadruplexes. Treatment with CX-3543 or with CX-1 
5461 eventually kills any cell, irrespective of its origin, but cancer cells, in particular those that 2 
have lost their ability to repair DNA damage, are particularly sensitive to treatment with both CX 3 
derivatives [41]. This is typically the case for BRCA-deficient cancer cells, and for polyclonal 4 
patient-derived xenografts (PDX), including tumors resistant to PARP inhibitors (poly ADP ribose 5 
polymerase) and/or to platinum salts [41]. The deleterious effect of CX-5461 on BRCA2-deficient 6 
cells was reported in two colorectal cell lines, one ovarian cell line, in breast tumor cells, and in 7 
bone osteosarcoma cells, vouching for the general applicability of treatments with G4 stabilizers 8 
in DNA-repair deficient background, while not calling the effect on Pol I activity into question 9 
[41].  10 
An important consequence of inhibiting drug-induced ribosome biogenesis is the activation of a 11 
regulatory loop known as nucleolar stress [49]. The nucleolar stress response is a p53-dependent 12 
anti-tumoral pathway activated following a dysfunction in ribosome biogenesis [50]. Briefly, in 13 
normal cells, the antitumor protein p53 is maintained at a low level as it is constitutively targeted 14 
to the proteasome for degradation by Hdm2-mediated ubiquitination. Upon stress inhibiting 15 
ribosome biogenesis, free unassembled ribosomal components accumulate. This is notably the case 16 
of the uL5-uL18-5S rRNA trimeric complex which titrates Hdm2, sequestering it away from p53 17 
[51,52]. The consequence of Hdm2 titration is the stabilization of p53 and the activation of a cell 18 
death program leading to the killing of the stressed cell. [footnote: Note that on the basis of 19 
structural conservation between the three kingdoms of life, a coherent nomenclature has recently 20 
been proposed for r-proteins [53]. In this unified nomenclature, RPL11 and RPL5 have been 21 
renamed uL5 and uL18, respectively]. It is quite remarkable that among the eighty ribosomal 22 
proteins, uL5 and uL18 are the most important for maintaining the structure of the nucleolus [6]. 23 
In addition, the cytotoxic activity of these compounds is not limited to p53-dependent apoptosis, 24 
 9 
since other cell death modalities were reported including necrosis, senescence and autophagy, thus 1 
broadening the potential application of inhibitors of ribosome biogenesis for killing cancer cells 2 
[36–39]. However, the fine molecular mechanisms underlying these effects have as yet not been 3 
elucidated. Furthermore, the deleterious effects of CX-5461 have been observed in cells and 4 
polyclonal PDX models that lack p53 [41]. 5 
The rationale for establishing ribosome biogenesis as a druggable pathway in cancer therapeutics 6 
further resides in the observation that CX-derivatives and BMH-21 drugs seem to preferentially 7 
kill cancer cells, leaving “normal” untransformed cells less affected. For example, the CX-5461 8 
compound displays an IC50 of around 5 µM and 3 nM in non-transformed cells (e.g. BJ-hTert 9 
fibroblasts) and cancer cells (e.g. EOL-1 leukemia cells), respectively, while retaining the same 10 
Pol I inhibitory activity [38]. Drug selectivity is also supported by animal studies, in which these 11 
compounds displayed efficient antitumor activity without impacting the weight of mice over the 5-12 
week time course of the treatment [36,39,40]. In these studies, growth inhibition was observed 13 
using xenografts of pancreatic cancer MIA PaCa-2 cells (CX-3543 and CX-5461), melanoma A375 14 
cells (CX-5461 and BMH-21), and colorectal cancer HCT116 cells (BMH-21) [36–40]. Evaluation 15 
of CX-5461 in advanced phase I clinical trial for patients with BRCA1/2 deficient tumors is 16 
ongoing in Canada (NCT02719977). CX-3543 has been assessed in solid and neuroendocrine 17 
tumors, and lymphomas as phase I/II studies in the US, and no other trial is currently active 18 
(https://clinicaltrials.gov). In conclusion, independent works have demonstrated that the 19 
pharmacological inhibition of ribosome biogenesis is an efficient means of preferentially killing 20 
cancer cells. This was a turning point in the demonstration that the nucleolus is a bona fide target 21 
for anti-cancer intervention [54,55].  22 
 23 
2) Limitations. 24 
 10 
 Although targeting ribosome production by inhibiting the function of Pol I appears to be appealing, 1 
several limitations have been identified that will have to be overcome to fulfill the requirements of 2 
further clinical developments. Firstly, not all cell lines are sensitive to Pol I inhibitors (see NCI60 3 
response [37–39]), and this is irrespective of their p53 status. Therefore, it is crucial to better 4 
understand the pathways modulating the sensitivity of cells to these inhibitors. Secondly, the tested 5 
compounds only have a limited selectivity towards rRNA genes. Indeed, both CX-derivatives and 6 
BMH-21 are DNA binding compounds that are able to directly interact with any DNA sequence 7 
that is GC-rich or contains G-quadruplex, which means that they can bind elsewhere in the genome 8 
than onto rDNA. As such, these compounds are not specific to Pol I, they preferentially affect Pol 9 
I because rDNA genes are enriched in GC- and G-quadruplex-motifs. Thirdly, there are reported 10 
cases of acquired resistance to CX-5461, indicating that the anticancer activity of the drug can 11 
somehow be bypassed.  12 
 13 
 14 
2.2 Targeting ribosome biogenesis at other levels than RNA synthesis 15 
rRNA synthesis is only one of several steps of ribosome biogenesis that represents a druggable 16 
target, another being pre-rRNA processing. Processing depends on dozens of trans-acting factors 17 
which can either be proteinaceous or ribonucleic in nature. In addition to the actual catalytic 18 
activities, directly responsible for RNA processing (i.e. the endo- and exoribonucleolytic 19 
activities), many factors contribute to the proper folding of pre-rRNAs to enable them to acquire a 20 
cleavage-competent conformation. This is notably the case of the C/D box small nucleolar RNAs 21 
(snoRNAs) U3 and U8 which interact with the pre-rRNA through the formation of Watson-Crick 22 
base-pairing interactions. U3 and U8 are essential for early and late pre-rRNA processing reactions 23 
leading to the formation of small and large ribosomal subunits, respectively [56]. Using a mouse 24 
 11 
xenograft model, it was recently shown that aggressive cancer cells in which the expression of U3 1 
or U8 was silenced lost their tumorigenic potential once implanted into the flanks of nude animals 2 
[56]. When tumors formed, these were not only smaller but also more heterogeneous in 3 
composition as a consequence of healthy tissue repopulating the microenvironment. Increased 4 
tumor heterogeneity, as established by positive emission tomography that relies on the use of a 5 
metabolic tracer, is considered to be a positive clinical parameter owing to the presence of healthy 6 
tissues [56]. Consistently, knockdown of fibrillarin, one of the essential proteins of the U3/U8 C/D 7 
box complex, resulted in the reduced growth of MCF7 xenografts [57]. 8 
Other steps of ribosome biogenesis that may also be targeted are ribosome assembly and chemical 9 
modification of its components. There are only a few known pharmacological inhibitors of 10 
ribosome assembly. The best characterized being diazaborin, which inhibits the formation of the 11 
large ribosomal subunit at a late stage in budding yeast [58]. The search is on for similar active 12 
compounds on human cells. Finally, the chemical modifications of rRNAs also constitute a crucial 13 
step of ribosome biogenesis that can be targeted to design anticancer drugs since they lead to the 14 
production of cancer ribosomes (see below). 15 
 16 
 17 
3. Targeting the function of ribosomes  18 
 19 
 20 
Owing to the central role of ribosomes in modulating gene expression, innovative therapeutics 21 
inhibiting their function could also be pertinent. Indeed, this would represent a novel means of 22 
reducing the translational capacity of cells, which plays a primary role in tumorigenesis (reviewed 23 
in [11]). The control of translation has also been proposed as a novel target to circumvent resistance 24 
 12 
to targeted therapies, for example by inhibiting the eIF4F translation initiation complex in the 1 
context of anti-BRAF and anti-MEK resistance [9]. However, similarly to inhibiting ribosomal 2 
subunit biogenesis, a major challenge remains to be addressed, namely the level of specificity of 3 
such an inhibition. Indeed, (i) would it target a particular transcript or a subset of transcripts? (ii) 4 
Would it preferentially target diseased than healthy cells? Despite these concerns, this is a rapidly 5 
developing field of research, and several molecules are already in use to treat human diseases, 6 
including neurodevelopmental syndromes and cancer [59]. Indeed, homoharringtonine, a natural 7 
plant alkaloid extracted from the Japanese plum-yew tree Cephalotaxus harringtonii, is an FDA-8 
approved drug in the treatment of chronic myeloid leukemia traditionally used in Chinese medicine 9 
(Figure 1 – Box 3), which functions by inhibiting translation. [footnote: Homoharringtonine is also 10 
known as omocetaxine mepesuccinate or Synribo®].  11 
Alternatively, molecules that simultaneously target ribosome production (by blocking synthesis of 12 
components, or their assembly) and function (by blocking an active site on the ribosome) (Figure 13 
1 – Boxes 2 and 3) could be developed. One such case is haemanthamine, a natural alkaloid 14 
extracted from Daffodil bulbs, the anticancer properties of which have been used in folk medicine 15 
for centuries and have only recently been deciphered [60]. Indeed, it was demonstrated that this 16 
molecule targets both ribosome function, by sterically blocking translation, and ribosome 17 
production, by inhibiting RNA processing specifically; this latter property providing the added 18 
advantage of a potent activation of the nucleolar stress response leading to strong p53 stabilization 19 
[60].  20 
Combination therapy is routinely used in oncology and could enhance ribosome inhibition 21 
approaches. A direct effect of combining drugs is that the molecules are administered at lower 22 
concentrations thereby reducing their level of toxicity. The first attempts at combining Pol I 23 
inhibitor treatments with other drugs in vitro have revealed promising results, for example by 24 
 13 
combining CX-5461 with the mTOR inhibitor Everolimus on Myc-driven lymphoma xenograft 1 
[61], or by combining CX-5461 and the pan-PIM-kinase inhibitor CX-6258 on prostate cancer 2 
PDX [45]. Furthermore, combining molecules that target ribosome biogenesis and/or function with 3 
other anticancer treatments could prevent resistance and prolong the effects of individual drugs. 4 
For instance, as discussed above, inhibition of ribosome biogenesis results in an increase in the 5 
intracellular pool of free ribosomal proteins, which plays a major role in promoting apoptosis. 6 
Considering that free ribosomal proteins have a short half-life [62], drugs that target the 7 
proteasomes could be used to stabilize them. Finally, reducing the ribosome pool of cancer cells 8 
may weaken their metabolism and might render them more sensitive to stresses induced by other 9 
drugs. 10 
 11 
 12 
4. Targeting “cancer ribosomes”: myth or reality? 13 
 14 
 15 
Today we are facing a paradigm shift with the demonstration that cells do not produce ribosomes 16 
with a unique composition, but instead produce a variety of ribosomes that differ in their protein 17 
and RNA composition [24,63]. Ribosome composition was shown to vary in r-proteins or rRNAs 18 
according to the status of the cell, environmental conditions, developmental stages, or 19 
physiological and pathological conditions [64–73]. Interestingly, ground-breaking studies have 20 
demonstrated changes in rRNA composition in cancer cells supporting to the existence of cancer-21 
associated ribosome variants, exhibiting altered rRNA 2’-O-methylation [69,70]. In addition, 22 
mutations of the DKC1 gene encoding the pseudouridine synthase dyskerin were identified in 23 
dyskeratosis congenita patients, which are characterized by an increased cancer susceptibility. 24 
 14 
These patients display an altered rRNA pseudouridine content [72,74]. Hence, these findings 1 
substantiate the notion of cancer ribosomes (see definition in the introduction section). Continuous 2 
technological advances in mapping rRNA modifications and characterizing the ribosomal 3 
proteome will be instrumental in identifying cancer-specific ribosomal signatures and reinforcing 4 
the cancer ribosome hypothesis. 5 
Among the different types of RNA modifications, 2’-O-methylation (2’-O-Me) is the most 6 
abundant on eukaryotic rRNA with 55 and 106 sites mapped in yeast and in human rRNA, 7 
respectively [71,73,75–77]. 2’-O-Me patterns of such cancer ribosomes were shown to be different 8 
from those of their healthy counterparts, i.e. the level of 2’-O-Me at some of the sites was different 9 
[70]. Importantly, 2’-O-Me provides an unanticipated "plasticity" to rRNA and ribosomes, since 10 
changes in the 2’-O-Me pattern is a molecular means to affect ribosome composition, which in turn 11 
contributes to modulating ribosomal activity [69–71,78–81]. For instance, modulation of 2’-O-Me, 12 
may provide functional specificity to cancer ribosomes, favoring the translation of mRNAs with 13 
key roles in tumorigenesis, cell survival and resistance to chemotherapeutic treatments [70,71]. 14 
Interestingly, modifications in 2’-O-Me are associated with alterations of internal ribosome entry 15 
site (IRES)-dependent translation initiation, which is preferentially activated under stress (e.g. 16 
hypoxia or nutrient deprivation). The mRNA of many major genes implicated in tumorigenesis 17 
contain an IRES-element, including oncogenes (c-Myc), tumor suppressors (p53), growth factors 18 
and their receptors (IGF-1R, VEGF, FGF) and apoptosis modulators (XIAP, Bcl-xl) [11,82]. The 19 
alteration of 2’-O-Me levels was associated with increased IRES-dependent translation initiation 20 
of c-Myc, FGF, VEGF and IGF-1R [70]. How such regulatory mechanisms contribute to 21 
tumorigenesis in vivo remains to be explored. Interestingly, a similar role is attributed to 22 
pseudouridylation, which, remarkably, affects a different set of IRES-elements compared to 2’-O-23 
 15 
Me, and further supports the notion that chemical modifications of rRNA plays a central role in 1 
modulating the translational capacity of ribosomes, notably during tumorigenesis [74,83,84]. 2 
In humans, 2’-O-Me of rRNA is carried out by the methyl transferase fibrillarin associated with 3 
the RNA-binding protein 15.5 kDa and the core proteins NOP56 and NOP58 [85,86]. Methylation 4 
at each site is guided by snoRNAs from the C/D box snoRNA family, which carry a complementary 5 
sequence to the target rRNA [87]. As the mechanisms of partial rRNA modification remain largely 6 
unknown, it is interesting that progressively reducing the concentration of fibrillarin in cells only 7 
impacts a subset of the 106 2’-O-methylated nucleotides, and that these mostly correspond to 8 
positions that are naturally hypomodified [71,73]. This suggests that hypo-modification is 9 
regulated by limiting the amounts of specific functional snoRNPs [71,73,86]. Moreover, of these 10 
106 2’-O-Me sites, several are sensitive to the presence of p53 in cells [70,73], which may indicate 11 
that modulation of 2’-O-Me levels contribute to regulating cell proliferation or to other aspects of 12 
the tumor suppressive functions promoted by p53. In addition, fibrillarin controls the amount of 13 
ribosome production through various molecular mechanisms, including rDNA histone methylation, 14 
pre-rRNA processing, and pre-rRNA modification [88], and its expression is controlled by p53 15 
[70,73]. Therefore, targeting such a master regulator of ribosome biogenesis could also be a 16 
promising approach to interfere with the production of ribosomes. However, to our knowledge no 17 
inhibitors of fibrillarin have so far been described. 18 
Lastly, developing drugs directly targeting specific ribosome variants, such as cancer ribosomes, 19 
can seriously be envisaged in view of the mode of action of several antibiotics that bind to highly 20 
specific ribosomal structures [89]. In particular, recent structural analysis of prokaryotic and 21 
eukaryotic ribosomes demonstrated that selectivity of ligand [footnote: By ‘ligand’, we refer to any 22 
molecule that can bind to the ribosome, i.e. tRNA, r-protein, translational factor, or small molecule 23 
inhibitors, including antibiotics and compounds active towards eukaryotic ribosomes] binding is 24 
 16 
often provided by subtle differences in the structure of the ribosome [60,90–95]. For instance, the 1 
anticancer compound haemanthamine, presented above, binds exclusively to eukaryotic ribosomes, 2 
since its binding site is slightly different in bacterial compared to human ribosomes, and is 3 
consequently only active in human cells [60]. Interestingly, resistance to antibiotics often relies on 4 
chemical modifications of the ribosomes [90,96], illustrating that changes as faint as a single 5 
chemical modification are sufficient to prevent the binding of small molecule inhibitors. This 6 
provides the proof-of-concept that it may be possible to develop antibiotic-like molecules to target 7 
the ribosomes that accumulate in cancer cells providing they exhibit structural features that 8 
distinguish them, even slightly, from those of healthy cells. 9 
 10 
 11 
5. Conclusions and future directions  12 
 13 
 14 
In this commentary, we presented evidence that ribosome biogenesis and function have emerged 15 
as novel cellular processes that can be efficiently targeted to treat cancer. This description included 16 
strategies that are currently under evaluation in clinical trials (RNA synthesis inhibition), as well 17 
as those that we deem should be further investigated in the future (targeting ribosome variants with 18 
small molecule inhibitors). However, we are but at the dawn of anticancer ribosome therapeutics, 19 
and many essential questions remain, the most important being why cancer cells are more sensitive 20 
than healthy ones to drugs that inhibit ribosome production and/or function. We speculate that the 21 
propensity of cancer cells to rely on more abundant ribosome production and increased protein 22 
synthesis to sustain their unrestricted cell growth renders them more vulnerable to cellular 23 
alterations of ribosome levels. Alternatively, cancer cells may be rewired by compositionally and 24 
 17 
functionally different ribosomes, offering a theory based on the preponderance of the ‘quality’ of 1 
the ribosomes produced, rather that their ‘quantity’, in tumorigenesis. 2 
So far, inhibition of ribosome biogenesis has only been tested in a relatively limited number of 3 
cancer models, and should thus be evaluated more broadly, in particular in cancers with higher 4 
therapeutic demands (e.g. advanced pancreatic or colorectal cancer, triple negative breast cancer, 5 
and melanoma) or in those displaying stronger proliferative traits.  6 
 7 
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Figure legends 
Figure 1. Actionable steps of human ribosome biogenesis and function in anticancer therapeutics. 
Ribosome biogenesis starts in the nucleolus which forms around rDNA genes (up to 400 copies per cells 
in humans). A single pre-rRNA containing the 18S, 5.8S and 28S rRNA is synthesized by RNA Pol I. 
The processing of this pre-rRNA includes numerous cleavage steps that produce the mature 5’ and 3’ 
ends of each rRNA [97], and the addition of > 200 chemical modifications (2’-O-methylation, 
pseudouridylation, base acetylation, methylation, and aminocarboxypropylation) [98]. Concomitantly, 
these assemble with the 5S rRNA (synthesized in the nucleoplasm by RNA Pol III) and 80 r-proteins. 
These nuclear steps lead to the formation of pre-ribosomal subunits that are exported to the cytoplasm 
through nuclear pore complexes. In the cytoplasm, several quality control steps take place ensuring the 
capacity of the subunits to translate mRNAs. As detailed in the text, ribosome production and function 
can be pharmacologically targeted at several steps to preferentially kill cancer cells. The boxes illustrate 
some of the strategies and compounds that are currently being evaluated as therapeutic approaches, or 
that could be used in the future. 
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